

Qureight
"Accelerating drug development through AI-powered clinical data curation for lung and heart disease"
About Qureight
Qureight curates complex healthcare data to accelerate clinical trials and drug development for lung and heart disease. The company's AI-powered platform analyses clinical trial images, physiological data and blood-based biomarkers to identify new endpoints, build synthetic control arms and assess treatment impact with unprecedented precision. Pharmaceutical companies, contract research organisations and healthcare institutions use Qureight's technology to reduce drug development time and cost. The platform quantifies lung volumes, airways, pulmonary vessels and fibrosis from CT scans, structures data in real time and enables collaborative research across diseases including pulmonary fibrosis, pulmonary hypertension and lung cancer.


46
Team Members
2018
Founded
Series A
Funding
Hybrid
Work Environment
A world where every patient with lung and heart disease benefits from precise, data-driven treatments that transform outcomes and extend lives.
Advances the understanding of lung and heart disease through AI-powered data curation that accelerates clinical trials and brings life-changing drugs to patients faster.